




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07C 255/54, A61K 31/165	A1	(11) International Publication Number: WO 99/35125 (43) International Publication Date: 15 July 1999 (15.07.99)
(21) International Application Number: PCT/EP98/08157 (22) International Filing Date: 12 December 1998 (12.12.98) (30) Priority Data: 9727523.4 31 December 1997 (31.12.97) GB (71) Applicant (for all designated States except US): NEWRON PHARMACEUTICALS S.P.A. [IT/IT]; Via R. Lepetit, 34, I-21040 Gerenzano (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): PEVARELLO, Paolo [IT/IT]; Piazza San Pietro in Ciel d'Oro, 7/A, I-27100 Pavia (IT). VARASI, Mario [IT/IT]; Via Giambellino, 80, I-20146 Milan (IT). SALVATI, Patricia [IT/IT]; Via Valera, 16/C, I-20020 Arese (IT). POST, Claes [SE/SE]; Nässelvägen 5, S-193 34 Sigtuna (SE).		(81) Designated States: AL, BA, BG, BR, CA, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KR, LC, LK, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS



(57) Abstract

The use, in the manufacture of a medicament for use as an analgesic, of a compound which is an alpha-aminoamide of formula (I) wherein: A is a $-(\text{CH}_2)_m-$, $-(\text{CH}_2)_n-\text{X}-$ or $-(\text{CH}_2)_v-\text{O}-$ group wherein m is an integer of 1 to 4, n is zero or an integer of 1 to 4, X is $-\text{S}-$ or $-\text{NH}-$, and v is zero or an integer of 1 to 5; s is 1 or 2; R is a furyl, thienyl, or pyridyl ring of a phenyl ring; R_1 is hydrogen or C_1-C_4 alkyl; one of R_2 and R_3 is hydrogen and the other is hydrogen or C_1-C_4 alkyl optionally substituted by hydroxy or phenyl; or R_2 and R_3 taken together with the carbon atom to which they are linked form a C_3-C_6 cycloalkyl ring; or R_2 and R_3 are both methyl; R_4 is hydrogen or C_1-C_4 alkyl ring; or a pharmaceutically acceptable salt thereof.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS

The present invention relates to novel and known alpha-aminoamide compounds, to a process for their preparation, 5 to pharmaceutical composition containing them and to their use as therapeutic agents.

In particular, the compounds of the present invention are endowed with analgesic properties and are particularly useful for the treatment and alleviation of chronic and 10 neuropathic pain.

Chronic and neuropathic pain are associated with prolonged tissue damage or injuries to the peripheral or central nervous system and result from a number of complex changes in nociceptive pathways.

15 Clinical manifestations of chronic pain include a sensation of burning or electric shock, feelings of bodily distortion, allodynia and hyperpathia.


Despite the large number of available analgesics, their use is limited by severe side effects and modest activity in 20 some pain conditions. Therefore there is still a clear need to develop new compounds.

International applications WO 90/14334, WO 94/22808, WO 97/05102 and WO 97/05102 disclose substituted benzylaminopropionamide compounds active on the central 25 nervous system and useful as anti-epileptic, anti-Parkinson, neuroprotective, antidepressant, antispastic and hypnotic agents.

The present invention is based on the finding that compounds known from the above-cited international 30 applications and new ones, closely related thereto, have

analgesis properties in mammals, including humans.

Accordingly, one object of the present invention is to provide the use of a compound of formula (I)



5

wherein:

A is a $-(\text{CH}_2)_m-$, $-(\text{CH}_2)_n-\text{X}-$ or $-(\text{CH}_2)_v-\text{O}-$ group wherein m is an integer of 1 to 4, n is zero or an integer of 1 to 4, X is $-\text{S}-$ or $-\text{NH}-$, and v is zero or an integer of 1 to 5;
s is 1 or 2;

10

R is a furyl, thienyl, or pyridyl ring or a phenyl ring optionally substituted by one or two substituents independently chosen from halogen, cyano, C_1-C_4 alkyl, C_1-C_4 alkoxy and trifluoromethyl;

15 R_1 is hydrogen or C_1-C_4 alkyl;

one of R_2 and R_3 is hydrogen and the other is hydrogen or C_1-C_4 alkyl optionally substituted by hydroxy or phenyl; or R_2 and R_3 taken together with the carbon atom to which they are linked form a C_3-C_6 cycloalkyl ring; or R_2 and R_3 are both methyl;

20

R_4 is hydrogen or C_1-C_4 alkyl ring;

or a pharmaceutically acceptable salt thereof;

and wherein

when A is a $-(\text{CH}_2)_5-\text{O}-$ group then s is 1, R is a phenyl group optionally substituted by one or two substituents selected independently from halogen, trifluoromethyl and C_1-C_4 alkoxy, R_1 is hydrogen and one of R_2 and R_3 is hydrogen and the other is hydrogen or C_1-C_4 alkyl

25

optionally substituted hydroxy;
and wherein

when R_2 and R_3 are both methyl then R is other than furyl, thienyl or pyridyl ring, in the manufacture of a medicament for use as analgesic, in particular for the treatment and alleviation of chronic and neuropathic pain.

A $-(CH_2)_m-$, $-(CH_2)_n-$ or $-(CH_2)_v-$ chain may be a branched or straight chain.

Alkyl and alkoxy groups may be branched or straight groups. Representative examples of C_1 - C_4 alkyl groups include methyl, ethyl, n- and iso-propyl, n-, iso-, sec- and tert-butyl.

Representative examples of C_1 - C_4 alkoxy groups include methoxy and ethoxy.

A C_3 - C_6 cycloalkyl group is for instance cyclopropyl, cyclopentyl or cyclohexyl, in particular cyclopentyl or cyclohexyl.

A halogen atom is fluorine, bromine, chlorine or iodine, in particular, chlorine or fluorine.

Pharmaceutically acceptable salts of the compounds of the invention include acid addition salts with inorganic, e.g. nitric, hydrochloric, hydrobromic, sulphuric, perchloric and phosphoric acids or organic, e.g. acetic, trifluoroacetic, propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic and salicylic acids.

The compounds of formula (I) have asymmetric carbon atoms and therefore they can exist either as racemic mixtures or

as individual optical isomers (enantiomers).
Accordingly, the present invention also include within its
scope all the possible isomers and their mixtures and both
the metabolites and the pharmaceutically acceptable bio-
5 precursors (otherwise known as pro-drugs) of the compounds
of formula (I).

Preferred compounds of formula (I) are those wherein

- A is a group chosen from $-\text{CH}_2-$, $-\text{CH}_2-\text{CH}_2-$, $-\text{CH}_2-\text{S}-$,
10 $-\text{CH}_2-\text{CH}_2-\text{S}-$ and $-(\text{CH}_2)_v-\text{O}-$ in which v is an integer of 1
to 5;
s is 1 or 2;
R is a phenyl ring optionally substituted by one or two
substitutents independently chosen from halogen and
15 cyano or a thienyl ring;
 R_1 is hydrogen or C_1-C_4 alkyl;
one of R_2 and R_3 is hydrogen and the other is C_1-C_4 alkyl
optionally substituted by hydroxy or phenyl; or R_2 and R_3
are both methyl;
20 R_4 is hydrogen or C_1-C_4 alkyl; and the pharmaceutically
acceptable salts thereof.

Examples of specific compounds of formula (I) are:

- 2-[4-(3-fluorobenzyloxy)benzylamino]-2-methyl-propanamide;
25 2-[4-(3-fluorobenzyloxy)benzylamino]propanamide;
2-([4-benzyloxybenzylamino]propanamide;
2-[4-(2-fluorobenzyloxy)benzylamino]propanamide;
2-[4-(4-fluorobenzyloxy)benzylamino]propanamide;
2-[4-(2-chlorobenzyloxy)benzylamino]propanamide;

- 2-[4-(3-chlorobenzyloxy)benzylamino]propanamide;
2-[4-(3-fluorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;
2-[4-(2-fluorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;
5 2-[4-(2-chlorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;
2-[4-(3-cyanobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;
10 2-[4-(3-chlorobenzyloxy)phenylethylamino]-propanamide;
2-(4-benzyloxybenzylamino)-3-hydroxy-N-methyl-propanamide;
2-(4-(2-thenyloxy)benzylamino)-propanamide;
2-[4-(3-fluorobenzyloxy)benzylamino]-N-methylpropanamide;
2-[4-(3-fluorobenzyloxy)benzylamino]-3-hydroxy-propanamide;
15 2-[4-(2-(3-fluorophenyl)ethyloxy)benzylamino]-propanamide;
2-[4-(2-(3-fluorophenyl)ethyl)benzylamino]-propanamide;
2-[N-4-benzyloxybenzyl-N-methyl-amino]-propanamide;
2-[2-(4-(3-chlorobenzyloxy)phenylethyl)amino]-propanamide;
2-[4-benzylthiobenzylamino]-propanamide;
20 2-[4-(3-phenylpropyloxy)benzylamino]-propanamide;
2-[4-(4-phenylbutyloxy)benzylamino]-propanamide;
2-[4-(5-phenylpentyloxy)benzylamino]-propanamide;
2-[4-benzyloxybenzylamino]-3-phenyl-N-methylpropanamide;
2-[4-benzyloxybenzylamino]-3-methyl-N-methylbutanamide, if
25 the case either as a single isomer or as a mixture thereof,
and the pharmaceutically acceptable salts thereof.

An aspect of this invention relates to a pharmaceutically composition having analgesic activity, in particular against chronic and neuropathic pain, comprising a compound of formula (I), as herein defined, as an active agent and a
5 pharmaceutically acceptable salt thereof.

A further aspect of this invention relates to a method of treating a mammal, including humans, in need of an analgesic agent, said method comprising administering
10 thereto an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

Neuropathic and chronic pain conditions in a mammal can thus be alleviated and treated. Examples of pain conditions
15 that can be treated by a compound of formula (I) include:


- peripheral neuropathies, such as trigeminal neuralgia, postherapeutic neuralgia, diabetic neuropathy, glossopharyngeal neuralgia, radiculopathy, and neuropathy secondary to metastatic infiltration, adiposis dolorosa and
20 burn pain; and
- central pain conditions following stroke, thalamic lesions and multiple sclerosis.

"Treatment" as used herein covers any treatment of a condition in a mammal, particularly a human, and includes:

- 25 (i) preventing the disease from occurring in a subject which may be predisposed to the disease, but has not yet been diagnosed as having it;
- (ii) inhibiting the condition, i.e., arresting its development; or
- 30 (iii) relieving the condition, i.e., causing

regression of the disease.

Another object of the present invention are the novel compounds of formula (IA)



5

wherein:

A is a $-(\text{CH}_2)_m-$ or $-(\text{CH}_2)_n-\text{E}-$ group wherein m is an integer of 1 to 4, n is zero or an integer of 1 to 4 and E is $-\text{O}-$, $-\text{S}-$ or $-\text{NH}-$;

10 s is 1 or 2;

one of R_{10} and R_{11} is cyano and the other is independently selected from hydrogen, halogen, cyano, C_1-C_4 alkyl, C_1-C_4 alkoxy and trifluoromethyl;

R_1 is hydrogen or C_1-C_4 alkyl;

15 one of R_2 and R_3 is hydrogen and the other is hydrogen or C_1-C_4 alkyl optionally substituted by hydroxy or phenyl; or R_2 and R_3 taken together with the carbon atom to which they are linked form a C_3-C_6 cycloalkyl ring; or R_2 and R_3 are both methyl;

20 R_4 is hydrogen or C_1-C_4 alkyl ring; and the pharmaceutically acceptable salts.

The compounds of formula (IA) fall within the scope of the compound of formula (I), as herein defined. Therefore all the definitions and biological properties stated above as to a compound of formula (I) apply also to a compound of formula (IA).

In particular, preferred compounds of formula (IA) are those wherein

A is a group $-\text{CH}_2-\text{O}-$ or $-\text{CH}_2-\text{CH}_2-\text{O}-$,

5 s is 1;

one of R_{10} and R_{11} is cyano and the other is hydrogen, cyano or halogen; and

one of R_2 and R_3 is hydrogen and the other is C_1-C_4 alkyl optionally substituted by hydroxy; or R_2 and R_3 are both methyl and the pharmaceutically acceptable salts thereof. ()


Specific examples of compounds of formula (IA) are:

2-[4-(3-cyanobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;
15 [2-[4-(3-cyanobenzyloxy)benzyl]-2-methyl-amino]-3-hydroxy-N-methyl-propanamide, if the case either as a single isomer or as a mixture thereof, and the pharmaceutically acceptable salts thereof.


20

The compounds of formula (I) and (IA) and the pharmaceutically acceptable salts thereof can be obtained by well known processes as described in the above cited international applications. In particular, a compound of
25 formula (IA) and the salts thereof can be obtained by a process comprising:


a) reacting a compound of formula (II)




wherein R_{10} , R_{11} , A and s are as defined above, with a compound of formula (III)



- 5 wherein R_2 , R_3 and R_4 are as defined above, thus obtaining a compound of formula (IA) in which R_1 is hydrogen; or
b) reacting a compound of formula (IV)



- wherein R_2 , R_3 , R_4 , R_{10} , R_{11} , A and s are as defined above,
10 with a compound of formula (V) or (VI)



- wherein W is a halogen atom; R'_5 is C_1 - C_4 alkyl and R''_5 is
15 hydrogen or C_1 - C_3 alkyl, thus obtaining a compound of formula (IA) in which R_1 is C_1 - C_4 alkyl; and, if desired, converting a compound of formula (IA) into another compound of formula (IA) and/or, if desired, converting a compound of formula (IA) into a pharmaceutically acceptable salt

and/or, if desired, converting a salt into a free compound.

All the processes described hereabove are analogy processes and can be carried out according to well known methods in organic chemistry.

A compound of formula (IV) is a compound of formula (IA) in which R_1 is hydrogen.

The reaction of a compound of formula (II) with a compound of formula (III) to give a compound of formula (IA) or (IV) is a reductive amination reaction which can be carried out according to well known methods. According to a preferred embodiment of the invention it may be performed under nitrogen atmosphere, in a suitable organic solvent, such as an alcohol, e.g. a lower alkanol, in particular methanol, or in acetonitrile, at a temperature ranging from about 0°C to about 40°C, in the presence of a reducing agent, the most appropriate being sodium cyanoborohydride.

Occasionally molecular sieves can be added to the reaction mixture for facilitating the reaction.

In a compound of formula (V) the halogen W is preferably iodine. The alkylation reaction of a compound of formula (IV) with a compound of formula (V) can be carried out in a suitable organic solvent, such as an alcohol, e.g. methanol, ethanol or isopropanol, in particular in ethanol, at a temperature ranging from about 0°C to about 50°C.

The alkylation reaction of a compound of formula (IV) with an aldehyde of formula (VI) can be carried out in a suitable organic solvent, such as an alcohol, e.g. methanol, ethanol or acetonitrile in the presence of a suitable reducing agent, such as sodium cyanoborohydride,

at a temperature ranging from about 0°C to about 30°C.

A compound of formula (IA) can be converted, as stated above, into another compound of formula (IA) by known methods. Process-variant b) above may be regarded as an
5 example of optional conversion of a compound of formula (IA) into another compound of formula (IA).

Also the optional salification of a compound of formula (IA) as well as the conversion of a salt into the free compound may be carried out by conventional methods.

10 The compounds of formula (II) and (III), (V) and (VI) are known compounds or can be obtained by known methods.

When in the compounds of the present invention and in the intermediate-products thereof, groups are present, which need to be protected before submitting them to the
15 hereabove illustrated reactions, they may be protected before being reacted and then deprotected according to methods well known in organic chemistry.

The compounds of formula (I), (IA) and the pharmaceutically acceptable salts thereof are hereinafter defined as "the
20 compounds of the invention" or "the active agents of the invention".

PHARMACOLOGY

As stated above, the compounds of the invention are active
25 as analgesic agents, as proven for instance by the fact that they have been found to be active in the formalin test.

Formalin test is a useful tool for obtaining neurogenic inflammation and continuous pain (Shibata et al, Pain, 38:
30 347-352, 1989).

Formalin produces a distinct biphasic response. The early phase seems to be caused predominantly by C-fibre activation due to peripheral stimulus, while the late phase appears to be dependent on the combination of an inflammatory reaction in the peripheral tissue and functional changes in the dorsal horn of the spinal cord. This functional changes seem to be initiated by the C-fibre barrage during the early phase (Tjolsen et al. Pain 51, 5-17, 1992). Substance P and bradykinin participate in the early phase, while histamine, serotonin, prostaglandins and bradykinin are involved in the late phase.

Formalin test

Male NMRI mice (22-25 g) were injected with 20 µl of 2.7% solution of formalin into the right hindpaw and placed immediately into observation chambers. The cumulative licking time of the injected paw was recorded in the acute phase (0-5 min) and in the chronic phase (30-40 min) of the nociceptive response of formalin.

The two representative compounds of the invention (S)-2-[4-(3-fluorobenzyloxy)benzylamino]-propanamide, methanesulfonate (internal code PNU 151774E) and (S)-[2-[4-(3-fluorobenzyloxy)benzylamino]-2-methyl-propanamide (internal code PNU 156654E) were administered 60 min before formalin injection at the doses of 7.5, 15.0, 30.0 and 60.0 mg/kg; po. Morphine (5 mg/kg; sc) was used as a positive standard. The activities data analysed by Dunnett's t-test.

Locomotor activity and Rotarod

The effects of these compounds on locomotor activity and rotarod (a test for evaluating motor co-ordination) were studied in order to exclude changes in these parameters as confounding factors in the evaluation of the formalin response. The locomotor activity test lasted 15 min. Five minutes after testing locomotor activity, the mice were put on the rotarod for 2 min and the number of mice falling within this time were counted.

Compounds PNU 151774E and PNU 156654E were tested at the doses of 7.5, 15.0, 30.0 and 60.0 mg/kg; po. The compounds were administered 60 min before locomotor activity test.

Results

Compounds PNU 151774E and PNU 156654E dose-dependently reduced cumulative licking time in both phases of the formalin test (Table 1) demonstrating analgesic activity without any effect on locomotor or rotarod activity (Table 2).

Table 1

Effects of PNU 151774E and PNU 156654E in the formalin nociception test in mice			
Compound	Dose (mg/kg; po)	Leukemia time (sec)	
		Acute phase	Chronic phase
vehicle	0.0	160.2 ± 2.6	74.8 ± 3.7
PNU 151774E	7.5	137.9 ± 2.4 ^a	72.4 ± 2.4
	15.0	87.9 ± 3.3 ^a	64.3 ± 2.8 ^b
	30.0	79.4 ± 3.0 ^a	56.9 ± 2.6 ^a
	60.0	63.1 ± 2.6 ^a	38.1 ± 3.6 ^a
vehicle	0.0	119.4 ± 5.2	73.1 ± 6.0
PNU 156654E	7.5	108.4 ± 4.2	62.4 ± 3.6
	15.0	79.7 ± 3.7 ^a	42.1 ± 6.2 ^a
	30.0	60.0 ± 2.3 ^a	37.7 ± 6.9 ^a
	60.0	44.4 ± 4.2 ^a	17.3 ± 6.6 ^a

^a = p < 0.01; ^b = p < 0.05

Table 2

Effects of PNU 151774E and PNU 156654E on locomotor activity and rotarod			
Compound	Dose (mg/kg; po)	Locomotor activity counts (mean \pm sem)	Rotarod co-ordination (mice fallen/ total mice)
vehicle	0	2653 \pm 163	0/10
PNU 151774E	7.5	2908 \pm 234	0/10
	15	2795 \pm 255	0/10
	30	2347 \pm 203	0/10
	60	2240 \pm 195	0/10
vehicle	0	1976 \pm 232	0/10
PNU 156654E	7.5	1966 \pm 188	0/10
	15	2110 \pm 256	0/10
	30	2272 \pm 317	0/10
	60	2119 \pm 310	0/10

In view of their biological activity, the compounds of the
 5 invention are useful in mammals, including humans, as
 analgesic agents. In particular they are useful in treating
 pain associated with damage or permanent alteration of the
 peripheral or central nervous system, for example
 peripheral neuropathies, such as trigeminal neuralgia,
 10 posttherapeutic neuralgia, diabetic neuropathy,
 raticulopathy, glossopharyngeal neuralgia, and neuropathy
 secondary to metastatic infiltration, adiposis dolorosa,

and burn pain; and central pain conditions following stroke, thalamic lesions and multiple sclerosis.

The conditions of a patient in need of an analgesic agent may thus be improved.

- 5 The compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form of suppositories; parenterally, e.g. intramuscularly, or by
10 intravenous injection or infusion.

The dosage depends on the age, weight, conditions of the patient and on the administration route; for example, the dosage adopted for oral administration to adult humans e.g. for the representative compounds of the invention

- 15 (S)-2-[4-(3-fluorobenzyloxy)benzylamino]-propanamide, methanesulfonate,

(S)-[2-[4-(3-fluorobenzyloxy)benzylamino]-2-methylpropanamide, and

- (S)-[2-[4-(3-cyanobenzyloxy)benzylamino]-3-hydroxy-N-
20 methylpropanamide may range from about 1 to about 500 mg pro dose, from 1 to 5 times daily.

- The invention includes pharmaceutical compositions comprising a compound of formula (IA), as an active principle, in association with a pharmaceutically
25 acceptable excipient (which can be a carrier or a diluent).

The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.

- 30 For example, the solid oral forms may contain, together

with the active compound, diluents, e.g. lactose, destrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; desegregating agents, e.g. a starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar-coating, or film-coating processes.

The liquid dispersion for oral administration may be e.g. syrups, emulsions and suspension.

The syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

The suspension and the emulsion may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.

The suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride. The solutions for intravenous injections or

infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

The suppositories may contain together with the active
5 compound a pharmaceutically acceptable carrier, e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.

The following examples illustrate but do not limit the
10 invention.

Example 1

(S)-2-[4-(3-cyanobenzyloxy)benzylamino]-3-hydroxy-N-methyl-
propanamide

15 To a solution of N-methylserinamide hydrochloride (2 g; 0.0129 mol), in methanol (40 ml), 2 g of powdered 3A molecular sieves are added; after stirring 15' at room temperature, 0.65 g (0.0102 mol) of sodium cyanoborohydride are added in a single portion followed by 2.85 g (0.012
20 mol) of 4-(3-cyanobenzyloxy)benzaldehyde. The mixture is stirred for 2 hours at room temperature, then filtered and the residue after evaporation is separated by flash-chromatography on silica gel (eluant: chloroform 98: methanol 2: 30% NH₄OH 0.2). 2.6 g (63%) of pure titled
25 compound (m.p. 130-134 °C).

$[\alpha]_D$: +12.8 (c = 1.25 AcOH)

Example 2

(S)-2-[4-(3-cyanobenzyloxy)benzylamino]-3-hydroxy-N-methyl-
30 propanamide

(S)-2-[4-(3-cyanobenzyloxy)benzylamino]-3-hydroxy-N-methyl-propanamide (2 g; 0.0059 mol) is dissolved in methanol (30 ml) and 1.8 g (0.013 mol) of anhydrous potassium carbonate are added to the solution. Methyl iodide (1.5 ml; 0.025 mol) is dropped into the mixture which is stirred for 2 hours at room temperature and then evaporated to dryness. The crude residue is chromatographed on silica gel (eluant: chloroform/methanol; 95/5). 1.88 g (90%) of (S)-[2-[4-(3-cyanobenzyloxy)benzyl]-2-methyl-amino]-3-hydroxy-N-methyl-propanamide are obtained.

Elemental Analysis:

Atom	Calc.	Found
C	67.97	67.69
H	6.56	6.48
15 N	11.89	11.98


Example 3

With the usual methods of pharmaceutical technique, preparation can be made of capsules having the following composition:

(S)-2-[4-(3-cyanobenzyloxy)benzylamino]-3-hydroxy-N-methyl-propanamide	50 mg
Talc	2 mg
Corn starch	2 mg
25 Microcristalline cellulose	6 mg
Magnesium stearate	1 mg

CLAIMS

1. Use, in the manufacture of a medicament for use as
 an analgesic, of a compound which is an alpha-aminoamide of
 5 formula (I)



wherein:

A is a $-(\text{CH}_2)_m-$, $-(\text{CH}_2)_n-\text{X}-$ or $-(\text{CH}_2)_v-\text{O}-$ group wherein m is
 an integer of 1 to 4, n is zero or an integer of 1 to 4,
 10 X is $-\text{S}-$ or $-\text{NH}-$, and v is zero or an integer of 1 to 5;
 s is 1 or 2;

R is a furyl, thienyl, or pyridyl ring or a phenyl ring
 optionally substituted by one or two substituents
 independently chosen from halogen, cyano, C_1-C_4 alkyl,
 15 C_1-C_4 alkoxy and trifluoromethyl;

R_1 is hydrogen or C_1-C_4 alkyl;

one of R_2 and R_3 is hydrogen and the other is hydrogen or
 C_1-C_4 alkyl optionally substituted by hydroxy or phenyl;
 or R_2 and R_3 taken together with the carbon atom to which
 20 they are linked form a C_3-C_6 cycloalkyl ring; or R_2 and R_3
 are both methyl;

R_4 is hydrogen or C_1-C_4 alkyl ring;

or a pharmaceutically acceptable salt thereof;

with the provisos that,

25 when A is a $-(\text{CH}_2)_5-\text{O}-$ group then s is 1, R is a phenyl
 group optionally substituted by one or two substituents
 selected independently from halogen, trifluoromethyl and
 C_1-C_4 alkoxy, R_1 is hydrogen and one of R_2 and R_3 is

hydrogen and the other is hydrogen or C₁-C₄ alkyl optionally substituted hydroxy;

and

when R₂ and R₃ are both methyl then R is other than a furyl, thienyl or pyridyl ring.

2. Use according to claim 1, wherein the medicament is for the treatment or alleviation of chronic or neuropathic pain.

3. Use according to claim 1, wherein, in formula (I)

A is a group chosen from -CH₂-, -CH₂-CH₂-, -CH₂-S-, -CH₂-CH₂-S- and -(CH₂)_v-O- in which v is an integer of 1 to 5;

s is 1 or 2;

R is a phenyl ring optionally substituted by one or two substituents independently chosen from halogen and cyano or a thienyl ring;

R₁ is hydrogen or C₁-C₄ alkyl;

one of R₂ and R₃ is hydrogen and the other is C₁-C₄ alkyl optionally substituted by hydroxy or phenyl; or R₂ and R₃ are both methyl; and

R₄ is hydrogen or C₁-C₄ alkyl.

4. Use according to claim 1, wherein the compound is selected from:

2-[4-(3-fluorobenzyloxy)benzylamino]-2-methyl-propanamide;

2-[4-(3-fluorobenzyloxy)benzylamino]propanamide;

2-([4-benzyloxybenzylamino)propanamide;


- 2-[4-(2-fluorobenzyloxy)benzylamino]propanamide;
2-[4-(4-fluorobenzyloxy)benzylamino]propanamide;
2-[4-(2-chlorobenzyloxy)benzylamino]propanamide;
2-[4-(3-chlorobenzyloxy)benzylamino]propanamide;
5 2-[4-(3-fluorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;
2-[4-(2-fluorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;
2-[4-(2-chlorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;
10 2-[4-(3-cyanobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;
2-[4-(3-chlorobenzyloxy)phenylethylamino]-propanamide;
2-(4-benzyloxybenzylamino)-3-hydroxy-N-methyl-propanamide;
15 2-(4-(2-thenyloxy)benzylamino)-propanamide;
2-[4-(3-fluorobenzyloxy)benzylamino]-N-methylpropanamide;
2-[4-(3-fluorobenzyloxy)benzylamino]-3-hydroxy-propanamide;
2-[4-(2-(3-fluorophenyl)ethyloxy)benzylamino]-propanamide;
2-[4-(2-(3-fluorophenyl)ethyl)benzylamino]-propanamide;
20 2-[N-4-benzyloxybenzyl-N-methyl-amino]-propanamide;
2-[2-(4-(3-chlorobenzyloxy)phenylethyl)amino]-propanamide;
2-[4-benzylthiobenzylamino]-propanamide;
2-[4-(3-phenylpropyloxy)benzylamino]-propanamide;
2-[4-(4-phenylbutyloxy)benzylamino]-propanamide;
25 2-[4-(5-phenylpentyloxy)benzylamino]-propanamide;
2-[4-benzyloxybenzylamino]-3-phenyl-N-methylpropanamide;
2-[4-benzyloxybenzylamino]-3-methyl-N-methylbutanamide, if

the case either as a single isomer or as a mixture thereof, or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition having analgesic activity, comprising a pharmaceutically acceptable excipient and, as an active agent, a compound as defined in claim 1.

6. A method of treating a mammal, including a human, in need of an analgesic agent, said method comprising administering thereto an effective amount of a compound of formula (I), as defined in claim 1, or a pharmaceutically acceptable salt thereof.

7. A compound which is an alpha-aminoamide of formula (IA)



wherein:

A is a $-(CH_2)_m-$ or $-(CH_2)_n-E-$ group wherein m is an integer of 1 to 4, n is zero or an integer of 1 to 4 and E is -O-, -S- or -NH-;

s is 1 or 2;

one of R_{10} and R_{11} is cyano and the other is independently selected from hydrogen, halogen, cyano, C_1-C_4 alkyl, C_1-C_4 alkoxy and trifluoromethyl;

R_1 is hydrogen or C_1-C_4 alkyl;

one of R_2 and R_3 is hydrogen and the other is hydrogen or

C₁-C₄ alkyl optionally substituted by hydroxy or phenyl; or R₂ and R₃ taken together with the carbon atom to which they are linked form a C₃-C₆ cycloalkyl ring; or R₂ and R₃ are both methyl;

- 5 R₄ is hydrogen or C₁-C₄ alkyl ring; or a pharmaceutically acceptable salt thereof.

8. A compound according to claim 7, wherein

A is a group -CH₂-O- or -CH₂-CH₂-O-,

- 10 s is 1;

one of R₁₀ and R₁₁ is cyano and the other is hydrogen, cyano or halogen; and

- one of R₂ and R₃ is hydrogen and the other is C₁-C₄ alkyl optionally substituted by hydroxy; or R₂ and R₃ are both methyl.
- 15

9. A compound selected from:

2-[4-(3-cyanobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide; and

- 20 [2-[4-(3-cyanobenzyloxy)benzyl]-2-methyl-amino]-3-hydroxy-N-methyl-propanamide, if the case either as a single isomer or as a mixture thereof, and the pharmaceutically acceptable salts thereof.

- 25 10. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and, as an active agent, a compound as defined in claim 7.

11. A compound as defined in claim 7 for use as in a method of treatment of the human or animal body by therapy.
- 30

12. A compound as claimed in claim 11 for use as an analgesic agent.

INTERNATIONAL SEARCH REPORT

Int .tional Application No

PCT/EP 98/08157

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C255/54 A61K31/165

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	PAOLO PEVARELLO ET AL.: "Synthesis and Anticonvulsant Activity of a New Class of 2-(Arylalkyl)aminoalkanamide Derivatives" JOURNAL OF MEDICINAL CHEMISTRY., vol. 41, no. 4, 12 February 1998, pages 579-590, XP002101390 WASHINGTON US see page 580, column 1, scheme 1; page 582, table 2, entry 60; page 583, column 2, table 5, entry 60; page 587, column 1, lines 36 - 45	7-11
A	EP 0 525 360 A (KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY) 3 February 1993 see page 1, line 1 - page 5, line 25; claims; examples	1-12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 April 1999

Date of mailing of the international search report

20/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Zervas, B

INTERNATIONAL SEARCH REPORT

Int. l. Application No
PCT/EP 98/08157

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GB 2 059 963 A (A. H. ROBINS COMPANY) 29 April 1981 see page 1, line 1 - line 50; claims; examples ----	1-12
A	WO 90 14334 A (FARMITALIA) 29 November 1990 cited in the application see page 1, line 21 - page 3, line 7; claims; examples ----	1-12
A	WO 97 05102 A (PHARMACIA & UPJOHN) 13 February 1997 cited in the application see page 1, line 1 - line 26; claims; examples -----	1-12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/08157

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 6
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 6
is directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compounds.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/08157

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 525360	A	03-02-1993	KR 9411133 B	23-11-1994
			KR 9411134 B	23-11-1994
			KR 9411149 B	24-11-1994
			DE 69224861 D	30-04-1998
			DE 69224861 T	06-08-1998
			JP 5320113 A	03-12-1993
			US 5242944 A	07-09-1994
GB 2059963	A	29-04-1981	AT 374170 B	26-03-1984
			AT 474580 A	15-08-1983
			AT 379740 B	25-02-1986
			AT 538481 A	15-07-1985
			AU 532359 B	29-09-1983
			AU 6211680 A	02-04-1981
			BE 885393 A	16-01-1981
			BR 8006042 A	07-04-1981
			CA 1128512 A	27-07-1982
			CH 646138 A	15-11-1984
			CS 227012 B	16-04-1984
			DE 3035688 A	16-04-1981
			DK 405780 A,B,	27-03-1981
			EG 15020 A	31-03-1985
			FI 803002 A,B,	27-03-1981
			FR 2465710 A	27-03-1981
			GR 70049 A	26-07-1982
			HK 59383 A	02-12-1983
			IE 50268 B	19-03-1986
			IN 151313 A	26-03-1983
			IN 155995 A	20-04-1985
			IN 156254 A	08-06-1985
			IN 156255 A	08-06-1985
			JP 1041616 B	06-09-1989
			JP 1559426 C	16-05-1990
			JP 56057751 A	20-05-1981
			KE 3307 A	19-08-1983
			LU 82797 A	10-05-1982
			NL 8005346 A	30-03-1981
			PH 22628 A	28-10-1988
			PT 71839 A,B	01-10-1980
			SE 448626 B	09-03-1987
			SE 8006668 A	27-03-1981
			US 4313949 A	02-02-1982
			YU 73083 A	31-12-1983
			YU 73183 A	31-12-1983
			ZA 8005476 A	25-11-1981
WO 9014334	A	29-11-1990	AT 96775 T	15-11-1993
			AU 645752 B	27-01-1994
			AU 5729990 A	18-12-1990
			CA 2033190 A	26-11-1990
			CN 1047496 A,B	05-12-1990
			CZ 9002520 A	12-06-1996
			DE 69004337 D	09-12-1993
			DE 69004337 T	24-02-1994
			DK 400495 T	06-12-1993
			EP 0400495 A	05-12-1990
			EP 0426816 A	15-05-1991
			ES 2062174 T	16-12-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. :ional Application No

PCT/EP 98/08157

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9014334 A		HU 9500703 A	28-12-1995
		IE 63934 B	28-06-1995
		IL 94466 A	24-01-1995
		JP 2771328 B	02-07-1998
		JP 4500215 T	16-01-1992
		NO 179944 B	07-10-1996
		PT 94160 A,B	08-01-1991
		RU 2097371 C	27-11-1997
		US 5391577 A	21-02-1995
		US 5502079 A	26-03-1996
		US 5276611 A	04-01-1994
		US 5236957 A	17-08-1993
		DD 298507 A	27-02-1992
WO 9705102 A	13-02-1997	AU 6418796 A	26-02-1997
		CA 2226894 A	13-02-1997
		CN 1192199 A	02-09-1998
		EP 0842143 A	20-05-1998
		NO 980290 A	22-01-1998
		PL 324639 A	08-06-1998